5-氯-4-甲基-2-(甲硫基)嘧啶 | 63331-71-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 5-氯-4-甲基-2-(甲硫基)嘧啶
• 英文名称: 5-chloro-4-methyl-2-(methylthio)pyrimidine
• 英文别名: 5-chloro-4-methyl-2-methylthiopyrimidine；5-chloro-4-methyl-2-methylsulfanyl-pyrimidine；2-methylthio-5-chloro-6-methylpyrimide；2-Methylthio-5-chlor-6-methylpyrimidin；5-chloro-4-methyl-2-methylsulfanylpyrimidine
• CAS: 63331-71-5
• 化学式: C₆H₇ClN₂S
• 分子量: 174.654
• InChiKey: UXQHFAHZZQURKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  51.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-氯-4-甲基-2-(甲硫基)嘧啶 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 4-Methyl-5-chlorpyrimid-2-on
  参考文献：
  名称：

  5-Halopyrimid-2-ones

  摘要：

  描述了具有有趣药理特性的嘧啶-2-酮的新衍生物。本发明的化合物已被发现可用于控制和特别是抑制恶性肿瘤和白血病的中期有用。还描述了制备新化合物的方法和含有它们的药物组合物。

  公开号：

  US04395406A1
• 作为产物：
  描述：

  5-chloro-6-methyl-2-(methylthio)pyrimidin-4(3H)-one 在 palladium on activated charcoal 、 氢气 、 sodium hydroxide 、 三氯氧磷 作用下， 以 水 、 N,N-二甲基苯胺 为溶剂， 20.0~115.0 ℃ 、206.85 kPa 条件下， 反应 39.0h， 生成 5-氯-4-甲基-2-(甲硫基)嘧啶
  参考文献：
  名称：

  Lead Optimization toward Proof-of-Concept Tools for Huntington’s Disease within a 4-(1H-Pyrazol-4-yl)pyrimidine Class of Pan-JNK Inhibitors

  摘要：

  Through medicinal chemistry lead optimization studies focused on calculated properties and guided by X-ray crystallography and computational modeling, potent pan-JNK inhibitors were identified that showed submicromolar activity in a cellular assay. Using in vitro ADME profiling data, 9t was identified as possessing favorable permeability and a low potential for efflux, but it was rapidly cleared in liver microsomal incubations. In a mouse pharmacokinetics study, compound 9t was brain-penetrant after oral dosing, but exposure was limited by high plasma clearance. Brain exposure at a level expected to support modulation of a pharmacodynamic marker in mouse was achieved when the compound was coadministered with the pan-cytochrome P450 inhibitor 1-aminobenzotriazole.

  DOI：

  10.1021/jm5013598

文献信息

• 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof
  申请人：CASELLAS Pierre

  公开号：US20070259847A1

  公开（公告）日：2007-11-08

  The disclosure relates to 2-amido-4-phenylthiazole derivatives of general formula (I) below: in which R 1 , R 2 , R 3 , Y, m, n, and p are as defined in the disclosure; as well as to their isomers, salts and solvates, to the pharmaceutical compositions containing them and to the therapeutic use thereof.

  该公开涉及通式（I）如下的2-酰胺-4-苯基噻唑衍生物：其中R1、R2、R3、Y、m、n和p如公开所定义；以及它们的异构体、盐和溶剂合物，包含它们的药物组合物以及其治疗用途。
• Substituted heteroarylamide oxazepinopyrimidone derivatives
  申请人：Sanofi-Aventis

  公开号：EP2085400A1

  公开（公告）日：2009-08-05

  A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: Y represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom substituted by a hydrogen atom or a C1-3 alkyl group, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 perhalogenated alkyl group or an amino group; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted by a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom; R2 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R3 represents a 4-15 membered heterocyclic group, this group being optionally substituted; R4 represents a hydrogen atom or a C1-6 alkyl group; and n represents 0 to 3 and their therapeutic use.

  一种由式（I）表示的吡啶酮衍生物或其盐，或其溶剂或水合物： 其中： Y代表两个氢原子，一个硫原子，一个氧原子或一个C1-2烷基和一个氢原子； Z代表键，一个氧原子，一个氮原子，该氮原子被一个氢原子或C1-3烷基取代，一个硫原子，一个亚甲基，该亚甲基可选地被选自C1-6烷基，羟基，C1-6烷氧基，C1-2全氟烷基或氨基的一或两个基团取代； R1代表2、3或4-吡啶环或2、4或5-嘧啶环，该环可选地被C1-6烷基，C1-6烷氧基或卤素原子取代； R2代表氢原子，C1-6烷基或卤素原子； R3代表4-15成员的杂环基，该基团可选地被取代； R4代表氢原子或C1-6烷基； n代表0到3及其治疗用途。
• HETEROARYLAMIDE PYRIMIDONE COMPOUNDS
  申请人：Lochead Alistair

  公开号：US20100087449A1

  公开（公告）日：2010-04-08

  The present invention discloses a series of pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: Wherein X, Z, R1, R2, R3, R4, R5, R6, R7, n and m are as defined herein. Also disclosed herein are the methods of preparation of compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.

  本发明揭示了一系列由公式(I)或其盐、溶剂或水合物表示的嘧啶酮衍生物：其中X、Z、R1、R2、R3、R4、R5、R6、R7、n和m如此定义。本发明还揭示了制备公式(I)化合物的方法、其中间体以及它们在治疗各种疾病条件中的用途。
• Benzimidazole derivatives and their use as protein kinases inhibitors
  申请人：Berdini Valerio

  公开号：US20070135477A1

  公开（公告）日：2007-06-14

  The invention provides compounds of the formula (1): The compounds have activity against cyclin depdenent kinases, glycogen synthase kinase and Auroa kinases and are therefore useful to treat cancer and viral diseases.

  该发明提供了式（1）的化合物： 这些化合物具有对环素依赖性激酶、糖原合成酶激酶和Auroa激酶的活性，因此可用于治疗癌症和病毒性疾病。
• SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES
  申请人：FAYOL Aude

  公开号：US20090306088A1

  公开（公告）日：2009-12-10

  A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof are disclosed and claimed. Wherein m, n, o, Y, Z, R1, R2, R3, R4, R5 R6 and R7 are as described herein. Also disclosed are the salts of compounds of formula (I). The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  本发明揭示和声明了由式(I)表示的吡啶酮衍生物，或其盐、溶剂或水合物。其中m、n、o、Y、Z、R1、R2、R3、R4、R5、R6和R7如本文所述。本发明还揭示了式(I)化合物的盐。本发明涉及一种药物，其包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，如阿尔茨海默病。